Literature DB >> 25920909

Extended pancreatoduodenectomy as defined by the International Study Group for Pancreatic Surgery is associated with worse survival but not with increased morbidity.

Philip R De Reuver1, Anubhav Mittal2, Michael Neale3, Anthony J Gill4, Jaswinder S Samra5.   

Abstract

BACKGROUND: Recently, the International Study Group for Pancreatic Surgery presented a consensus statement on the definition of an extended pancreatoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC). Because extended resections are associated with increased morbidity and mortality, prognostic factors for outcome are mandatory to optimize patient selection. The aim of this study was to apply the new definition of an extended PD and to assess prognostic factors for short-term complications and survival in patients with PDAC.
METHODS: A retrospective analysis was performed on a prospectively collected database running from 2004 to 2014. Inclusion criteria were all PD resections with histopathology-proven PDAC. Clinical data, operative results, and short- and long-term outcomes were analyzed.
RESULTS: We included 177 patients who underwent PD for PDAC in this study. Sixty-six patients (37%) underwent a standard PD and 111 (63%) underwent an extended PD. No differences were found in duration of postoperative stay (median, 13 days) or overall complication rate of 35% (n = 61). Severe complications occurred in 24 patients (13%). Male sex (odds ratio, 2.4; 95% CI, 0.9-6.6) was a prognostic factor for severe complications. There was no in-hospital or 90-day mortality in either group. Multivariate survival analysis showed that poor tumor differentiation (hazard ratio [HR], 2.0; 95% CI, 1.3-3.1), lymph node metastasis (HR, 2.3; 95% CI, 1.4-3.9), neural invasion (HR, 1.9; 95% CI, 1.2-3.1), were independent prognostic factors for worse survival. An extended resection was associated with worse survival, but was not an independent prognostic factor (HR, 1.5; 95% CI, 1.0-2.3).
CONCLUSION: Extended PD is associated with worse survival but not with increased morbidity.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25920909     DOI: 10.1016/j.surg.2015.03.015

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  6 in total

1.  Intra-operative amylase in peri-pancreatic fluid independently predicts for pancreatic fistula post pancreaticoduodectomy.

Authors:  Philip R de Reuver; Justin Gundara; Thomas J Hugh; Jaswinder S Samra; Anubhav Mittal
Journal:  HPB (Oxford)       Date:  2016-06-16       Impact factor: 3.647

2.  Extended pancreatectomy as defined by the ISGPS: useful in selected cases of pancreatic cancer but invaluable in other complex pancreatic tumors.

Authors:  Abhishek Mitra; Esha Pai; Rohit Dusane; Priya Ranganathan; Ashwin DeSouza; Mahesh Goel; Shailesh V Shrikhande
Journal:  Langenbecks Arch Surg       Date:  2018-01-23       Impact factor: 3.445

3.  Pancreatic Metastasectomy-an Analysis of Survival Outcomes and Prognostic Factors.

Authors:  Terence C Chua; Wilson Petrushnko; Anubhav Mittal; Anthony J Gill; Jaswinder S Samra
Journal:  J Gastrointest Surg       Date:  2016-02-18       Impact factor: 3.452

4.  Short-Term Outcomes of Extended Pancreatectomy: A Single-Surgeon Experience.

Authors:  Tze-Yi Low; Ye-Xin Koh; Jin-Yao Teo; Brian K P Goh
Journal:  Gastrointest Tumors       Date:  2017-11-30

5.  Technical details of a left-side approach to the superior mesenteric artery during pancreaticoduodenectomy.

Authors:  Katsunori Sakamoto; Kohei Ogawa; Akihiro Takai; Kei Tamura; Mikiya Shine; Takashi Matsui; Yusuke Nishi; Takeshi Utsunomiya; Hitoshi Inoue; Seiji Matsuda; Yasutsugu Takada
Journal:  Surg Today       Date:  2021-02-27       Impact factor: 2.549

Review 6.  Application and progress of medical imaging in total mesopancreas excision for pancreatic head carcinoma.

Authors:  Pei Feng; Bo Cheng; Zhen-Dong Wang; Jun-Gui Liu; Wei Fan; Heng Liu; Chao-Ying Qi; Jing-Jing Pan
Journal:  World J Gastrointest Surg       Date:  2021-11-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.